Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120562 | 0.82 | ALDH1A1 (0.49) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5122733 | 0.78 | ACHE (0.42) | MEN1KMT2ALMNAACHEALDH1A1 | |
| SCHEMBL17625991 | 0.78 | ALDH1A1 (0.49) | MAPK1CYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL5112239 | 0.77 | ACHE (0.47) | CYP1A2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL535336 | 0.77 | KDM4E (0.37) | MEN1KMT2AHPGDGAAKDM4E | |
| SCHEMBL536074 | 0.75 | LMNA (0.38) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL535505 | 0.75 | KDM4E (0.35) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL536187 | 0.75 | KDM4E (0.35) | MEN1KMT2AHPGDGAAKDM4E | |
| SCHEMBL6168172 | 0.75 | GRN (0.41) | SMN1; SMN2HPGDGAAKDM4EALDH1A1 | |
| SCHEMBL536126 | 0.73 | SMN1; SMN2 (0.44) | RAB9ASMN1; SMN2GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | claimed |
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-19 | — | — | US | claimed |
| WO-2009079593-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | claimed |
| US-20070275981-A1 | (Hetero)Cyclycarboxamides for Controlling Pathogenic Fungi | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1791427-A1 | (HETERO)CYCLYLCARBOXAMIDES FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2007-06-06 | — | — | EP | claimed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | claimed |
| EP-1747206-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2006027198-A1 | (HETERO)CYCLYLCARBOXAMIDES FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-16 | — | — | WO | claimed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | claimed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | claimed |
| US-5789618-A | Synthetic method for a halogen-containing condensation product | KONICA CORPORATION (JP) | 1998-08-04 | — | — | US | claimed |
| US-4045423-A | MONOAZO DYES | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1977-08-30 | — | — | US | claimed |
| EP-3682873-B1 | SMAC MIMETICS FOR USE IN THE TREATMENT OF PERSISTENT HIV INFECTION | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2024-06-12 | — | — | EP | disclosed |
| US-4045423-A | MONOAZO DYES | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1977-08-30 | — | — | US | disclosed |
| US-4045423-A | MONOAZO DYES | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | MAPK1 1340/4885CYP1A2 1438/4885CYP2C19 1300/4885 |
| US-20070275981-A1 | (Hetero)Cyclycarboxamides for Controlling Pathogenic Fungi | CBR3, CBR1, RPS10 | MAPK1 4195/4885CYP1A2 1473/4885CYP2C19 2183/4885 |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | P2RX7, P2RX2, P2RX5 | MAPK1 3112/4885CYP1A2 1272/4885CYP2C19 1195/4885 |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | MAPK1 2982/4885CYP1A2 4391/4885CYP2C19 4101/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | MAPK1 3112/4885CYP1A2 1272/4885CYP2C19 1195/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | MAPK1 3144/4885CYP1A2 1202/4885CYP2C19 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.